The clinical pharmacology of methotrexate.new applications of an old drug
- 1 January 1978
Abstract
Methotrexate is now used widely for the treatment of acute leukemia, non-Hodgkin's lymphoma, osteogenic sarcoma, choriocarcinoma, breast carcinoma, pulmonary and epidermoid carcinoma, and intrathecal chemotherapy. It is also useful in bone marrow transplantation, severe psoriasis, rheumatoid arthritis, dermatomyositis, Wegener's granulomatosis and sarcoidosis. The recent dramatic intensification of methotrexate therapy can be attributed in part to advances in our understanding of the clinical pharmacology of the folate antagonists, as well as to the combination of positive results and their effective dissemination to medical oncologists. The review summarizes the pharmacologic findings and illustrates how they are currently being applied to the treatment of malignant disease.This publication has 81 references indexed in Scilit:
- Methotrexate: clinical pharmacology, current status and therapeutic guidelinesCancer Treatment Reviews, 1977
- Computed Tomographic Appearance of Methotrexate-Induced Necrotizing LeukoencephalopathyRadiology, 1977
- Neurotoxicity and Elevated Cerebrospinal-Fluid Methotrexate Concentration in Meningeal LeukemiaNew England Journal of Medicine, 1973
- Methyltetrahydrofolic Acid Mediates N - and O -Methylation of Biogenic AminesScience, 1973
- Enzymatic Cleavage of Methotrexate provides a Method for Prevention of Drug ToxicityNature, 1972
- Immunologic Suppression by Methotrexate in DermatologySouthern Medical Journal, 1972
- Methotrexate Therapy of Wegener's GranulomatosisAnnals of Internal Medicine, 1971
- Acute Lymphocytic Leukemia in ChildrenPublished by American Medical Association (AMA) ,1969
- Long-term remissions following one and two-dose chemotherapy for African lymphomaCancer, 1967
- Increased Level of Dihydrofolic Reductase in Leucocytes of Patients Treated with AmethopterinNature, 1962